Galapagos receives transparency notification from Johnson & Johnson
Mar 01, 2016 21:10 pm UTC| Business
MECHELEN, Belgium, March 1, 2016 -- Galapagos NV (Euronext NASDAQ: GLPG) received a transparency notification from Johnson Johnson. Pursuant to Belgian transparency legislation[1], Galapagos received a transparency...
BOK Financial Closes on Weaver Wealth Management Transaction
Mar 01, 2016 21:08 pm UTC| Business
TULSA, Okla., March 01, 2016 -- BOK Financial Corporation (NASDAQ:BOKF) announces the completion of the asset purchase transaction with Weaver and Tidwell Financial Advisors LTD d/b/a Weaver Wealth Management, a...
RCM Technologies, Inc. Announces Fourth Quarter and Full Year 2015 Results
Mar 01, 2016 21:05 pm UTC| Business
PENNSAUKEN, N.J., March 01, 2016 -- RCM Technologies, Inc. (Nasdaq:RCMT), a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the...
Avinger, Inc. Announces Fourth Quarter and Full Year 2015 Results
Mar 01, 2016 21:05 pm UTC| Business
Pantheris™ Commercial Launch Underway REDWOOD CITY, Calif., March 01, 2016 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for...
Dermira to Report Fourth Quarter and Full Year 2015 Financial Results
Mar 01, 2016 21:05 pm UTC| Business
MENLO PARK, Calif., March 01, 2016 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of...
Guggenheim Investments Announces March 2016 Closed-End Fund Distributions
Mar 01, 2016 21:05 pm UTC| Business
NEW YORK, March 01, 2016 -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund...
Versartis to Present at the Cowen and Company 36th Annual Health Care Conference
Mar 01, 2016 21:05 pm UTC| Business
MENLO PARK, Calif., March 01, 2016 -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone...